Page last updated: 2024-09-03

gefitinib and Cancer of the Urinary Tract

gefitinib has been researched along with Cancer of the Urinary Tract in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bajorin, D; Halabi, S; Philips, GK; Sanford, BL; Small, EJ	2
Atkins, JN; Crawford, ED; Goodwin, JW; Kakhil, SR; Lange, MK; Mansukhani, M; Petrylak, DP; Tangen, CM; Twardowski, PW; Van Veldhuizen, PJ	1
Abbou, CC; Bakkar, A; Chopin, DK; Daher, A; de Medina, SG; Loric, S; Maillé, P; Nicolle, G; Radvanyi, F; Thiery, JP; Vacherot, F; Van der Kwast, T; Vermey, M; Vordos, D; Wallerand, H	1

Trials

3 trial(s) available for gefitinib and Cancer of the Urinary Tract

Article	Year
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Urologic Neoplasms	2009
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU international, 2010, Volume: 105, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium	2010
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU international, 2008, Volume: 101, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium	2008

Other Studies

1 other study(ies) available for gefitinib and Cancer of the Urinary Tract

Article	Year
Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-01, Volume: 12, Issue:9 Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Urologic Neoplasms	2006

Article

Year

Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-01, Volume: 12, Issue:9

Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Urologic Neoplasms

2006